ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AGN 194204

Also written as “IRX4204”, “NRX 194204” and “NRX194204”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Psoriasis · Prostatic Neoplasms · Parkinson Disease, led by 2 companies.

Drug pageAGN 194204: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Nov 13, 20115 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Io Therapeuticsits history only40 open or runningphase 2since Nov 13, 2011Nov 13, 2011none ahead
NuRx Pharmaceuticals10 open or runningphase 2since Aug 20, 2009Aug 20, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of NuRx Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2009First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT00964132 · 48 enrolled · United States

TargetBeta

“Retinoid X receptor agonist”ChEMBL 37, by rule

Studies

The one study NuRx Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00964132Carcinoma, Non-Small-Cell Lung · United States2UNKNOWNMar 201048

How it is read

Names in the registry

  • “IRX4204”, 3 entries
  • “NRX 194204”, 1 entry
  • “NRX194204”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.